ARTICLE | Company News
Vertex, Mitsubishi Pharma Ltd. deal
June 21, 2004 7:00 AM UTC
Mitsubishi received exclusive development and marketing rights to VRTX's VX-950 oral protease inhibitor to treat HCV infection in Japan and certain Far East countries. VRTX expects to receive up to $...